PC-025 · nootropic · cerebrolysin
Cerebrolysin
FPF 1070
Also: Brain peptide preparation
§ Overview
A multi-peptide mixture derived from porcine brain tissue, containing neurotrophic factors and free amino acids. Cerebrolysin has been approved in many countries (not US/UK) for stroke, traumatic brain injury, and dementia. It's one of the most clinically studied neuropeptide preparations.
§ Mechanism
Contains a mixture of neurotrophic peptides that mimic the action of BDNF, NGF, CNTF, and GDNF. Promotes neuronal survival, synaptic plasticity, neurogenesis, and reduces amyloid beta aggregation. Crosses the blood-brain barrier due to its small peptide fraction.
§ Common Uses
- → Stroke recovery
- → Traumatic brain injury
- → Dementia/Alzheimer's
- → Cognitive enhancement
- → Neuroprotection
§ Reported Side Effects
- · Dizziness
- · Headache
- · Injection site pain
- · Insomnia
- · Agitation (rare)
§ Research, Experiences & Trends
Mechanism of Action
Contains a mixture of neurotrophic peptides that mimic the action of BDNF, NGF, CNTF, and GDNF. Promotes neuronal survival, synaptic plasticity, neurogenesis, and reduces amyloid beta aggregation. Crosses the blood-brain barrier due to its small peptide fraction.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Dizziness
- • Headache
- • Injection site pain
- • Insomnia
- • Agitation (rare)